Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAP Prevacid maintenance of healed erosive esophagitis indication approved April 8.

Executive Summary

TAP PREVACID MAINTENANCE OF HEALED EROSIVE ESOPHAGITIS INDICATION APPROVED by FDA April 8. The proton pump inhibitor lansaprazole has a recommended daily dose of 15 mg for the new indication. The delayed-release capsule PPI from the joint venture Takeda-Abbott Pharmaceuticals originally was approved May 10, 1995 for short-term treatment for healing and symptom relief of active duodenal ulcer and erosive esophagitis and for long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome ("The Pink Sheet" May 15, 1995, p. 3).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel